Details for New Drug Application (NDA): 050797
✉ Email this page to a colleague
The generic ingredient in ZMAX is azithromycin. There are thirty-two drug master file entries for this compound. Sixty-seven suppliers are listed for this compound. Additional details are available on the azithromycin profile page.
Summary for 050797
Tradename: | ZMAX |
Applicant: | Pf Prism Cv |
Ingredient: | azithromycin |
Patents: | 2 |
Medical Subject Heading (MeSH) Categories for 050797
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION, EXTENDED RELEASE;ORAL | Strength | EQ 2GM BASE/BOT | ||||
Approval Date: | Jun 10, 2005 | TE: | RLD: | Yes | |||||
Patent: | 6,984,403 | Patent Expiration: | Feb 14, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | METHOD OF TREATING BACTERIAL INFECTIONS | ||||||||
Patent: | 7,887,844 | Patent Expiration: | Feb 14, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 050797
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pf Prism Cv | ZMAX | azithromycin | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 050797-001 | Jun 10, 2005 | 6,068,859 | ⤷ Subscribe |
Pf Prism Cv | ZMAX | azithromycin | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 050797-001 | Jun 10, 2005 | 7,887,844 | ⤷ Subscribe |
Pf Prism Cv | ZMAX | azithromycin | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 050797-001 | Jun 10, 2005 | 6,984,403 | ⤷ Subscribe |
Pf Prism Cv | ZMAX | azithromycin | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 050797-001 | Jun 10, 2005 | 6,268,489 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription